MAPT and Alzheimer disease: More recently, a prospective trial of 6-months estrogen therapy in HRT-naïve cognitively healthy and younger menopausal women showed longitudinal changes in AB/p-tau ratio scores for women within the HRT arm; these effects strongest for APOE4 carriers (Depypere et al., 2023), indicating, for the first time, potential positive effects of HRT on biomarkers relating to AD pathophysiology.